Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells - PubMed (original) (raw)
. 2012 Oct 1;18(19):5374-86.
doi: 10.1158/1078-0432.CCR-12-0736. Epub 2012 Sep 5.
Marcus M Fischer, Mark Hynes, Jingjiang Wu, Edward Kim, Lucia Beviglia, V Pete Yeung, Xiaomei Song, Ann M Kapoun, John Lewicki, Austin Gurney, Diane M Simeone, Timothy Hoey
Affiliations
- PMID: 22952347
- DOI: 10.1158/1078-0432.CCR-12-0736
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells
Wan-Ching Yen et al. Clin Cancer Res. 2012.
Abstract
Purpose: We previously showed that targeting Delta-like ligand 4 (DLL4) in colon and breast tumors inhibited tumor growth and reduced tumor initiating cell frequency. In this report, we have extended these studies to pancreatic cancer and probed the mechanism of action in tumor and stromal cells involved in antitumor efficacy.
Experimental design: Patient-derived pancreatic xenograft tumor models were used to evaluate the antitumor effect of anti-DLL4. To investigate the mechanism of action, we compared the activity of targeting DLL4 in tumor cells with an anti-human DLL4 antibody (anti-hDLL4) and in the host stroma/vasculature with an anti-mouse DLL4 antibody (anti-mDLL4). The effect of these antibodies on cancer stem cell frequency was examined by in vivo limiting dilution assays.
Results: The combination of anti-hDLL4 and anti-mDLL4 was efficacious in a broad spectrum of pancreatic tumor xenografts and showed additive antitumor activity together with gemcitabine. Treatment with either anti-hDLL4 or anti-mDLL4 delayed pancreatic tumor recurrence following termination of gemcitabine treatment, and the two together produced an additive effect. Anti-hDLL4 had a pronounced effect in reducing the tumorigenicity of pancreatic cancer cells based on serial transplantation and tumorsphere assays. In contrast, disruption of tumor angiogenesis with anti-mDLL4 alone or with anti-VEGF had minimal effects on tumorigenicity. Gene expression analyses indicated that anti-DLL4 treatment regulated genes that participate in Notch signaling, pancreatic differentiation, and epithelial-to-mesenchymal transition.
Conclusions: Our findings suggest a novel therapeutic approach for pancreatic cancer treatment through antagonism of DLL4/Notch signaling.
Similar articles
- Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH, Lee S, Kang HG, Park HW, Lee HW, Kim D, Yoem DH, Ahn JH, Ha E, You WK, Lee SH, Kim SJ, Chun KH. Kim DH, et al. BMB Rep. 2020 Nov;53(10):533-538. doi: 10.5483/BMBRep.2020.53.10.103. BMB Rep. 2020. PMID: 32580836 Free PMC article. - Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Li JL, et al. Cancer Res. 2007 Dec 1;67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969. Cancer Res. 2007. PMID: 18056450 - Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL, Muschel RJ. Liu SK, et al. J Natl Cancer Inst. 2011 Dec 7;103(23):1778-98. doi: 10.1093/jnci/djr419. Epub 2011 Oct 18. J Natl Cancer Inst. 2011. PMID: 22010178 - Delta-like 4/Notch signaling and its therapeutic implications.
Yan M, Plowman GD. Yan M, et al. Clin Cancer Res. 2007 Dec 15;13(24):7243-6. doi: 10.1158/1078-0432.CCR-07-1393. Clin Cancer Res. 2007. PMID: 18094402 Review. - Notch signaling regulates tumor angiogenesis by diverse mechanisms.
Dufraine J, Funahashi Y, Kitajewski J. Dufraine J, et al. Oncogene. 2008 Sep 1;27(38):5132-7. doi: 10.1038/onc.2008.227. Oncogene. 2008. PMID: 18758482 Free PMC article. Review.
Cited by
- The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.
Afzalipour R, Abbasi-Dokht T, Sheikh M, Mohammadlou M, Nili F, Baharlou R. Afzalipour R, et al. J Gastrointest Cancer. 2024 Sep;55(3):1380-1387. doi: 10.1007/s12029-024-01093-9. Epub 2024 Jul 24. J Gastrointest Cancer. 2024. PMID: 39046662 - Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.
Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D, Li L. Shi Q, et al. Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x. Signal Transduct Target Ther. 2024. PMID: 38797752 Free PMC article. Review. - The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development.
Fasoulakis Z, Koutras A, Ntounis T, Pergialiotis V, Chionis A, Katrachouras A, Palios VC, Symeonidis P, Valsamaki A, Syllaios A, Diakosavvas M, Angelou K, Samara AA, Pagkalos A, Theodora M, Schizas D, Kontomanolis EN. Fasoulakis Z, et al. Cancers (Basel). 2022 Mar 24;14(7):1649. doi: 10.3390/cancers14071649. Cancers (Basel). 2022. PMID: 35406423 Free PMC article. Review. - Understanding pancreatic cancer stem cells and their role in carcinogenesis: a narrative review.
Sumbly V, Landry I. Sumbly V, et al. Stem Cell Investig. 2022 Jan 19;9:1. doi: 10.21037/sci-2021-067. eCollection 2022. Stem Cell Investig. 2022. PMID: 35242873 Free PMC article. Review. - Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.
Zhdanovskaya N, Firrincieli M, Lazzari S, Pace E, Scribani Rossi P, Felli MP, Talora C, Screpanti I, Palermo R. Zhdanovskaya N, et al. Cancers (Basel). 2021 Oct 12;13(20):5106. doi: 10.3390/cancers13205106. Cancers (Basel). 2021. PMID: 34680255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical